ID   BMPR2_HUMAN             Reviewed;        1038 AA.
AC   Q13873; Q13161; Q16569; Q4ZG08; Q53SA5; Q585T8;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   10-MAY-2017, entry version 191.
DE   RecName: Full=Bone morphogenetic protein receptor type-2;
DE            Short=BMP type-2 receptor;
DE            Short=BMPR-2;
DE            EC=2.7.11.30;
DE   AltName: Full=Bone morphogenetic protein receptor type II;
DE            Short=BMP type II receptor;
DE            Short=BMPR-II;
DE   Flags: Precursor;
GN   Name=BMPR2; Synonyms=PPH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RC   TISSUE=Kidney;
RX   PubMed=7791754; DOI=10.1128/MCB.15.7.3479;
RA   Liu F., Ventura F., Doody J., Massague J.;
RT   "Human type II receptor for bone morphogenic proteins (BMPs):
RT   extension of the two-kinase receptor model to the BMPs.";
RL   Mol. Cell. Biol. 15:3479-3486(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Substantia nigra;
RX   PubMed=7644468; DOI=10.1073/pnas.92.17.7632;
RA   Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H.,
RA   ten Dijke P., Heldin C., Miyazono K.;
RT   "Cloning and characterization of a human type II receptor for bone
RT   morphogenetic proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7632-7636(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Skin fibroblast;
RX   PubMed=7673243; DOI=10.1074/jbc.270.38.22522;
RA   Nohno T., Ishikawa T., Saito T., Hosokawa K., Noji S., Wosing D.H.,
RA   Rosenbaum J.S.;
RT   "Identification of a human type II receptor for bone morphogenetic
RT   protein-4 that forms differential heteromeric complexes with bone
RT   morphogenetic protein type I receptors.";
RL   J. Biol. Chem. 270:22522-22526(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7890683; DOI=10.1074/jbc.270.10.5625;
RA   Kawabata M., Chytil A., Moses H.L.;
RT   "Cloning of a novel type II serine/threonine kinase receptor through
RT   interaction with the type I transforming growth factor-beta
RT   receptor.";
RL   J. Biol. Chem. 270:5625-5630(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-586, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-379, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [10]
RP   INTERACTION WITH GDF5.
RX   PubMed=21976273; DOI=10.1002/jbmr.532;
RA   Schwaerzer G.K., Hiepen C., Schrewe H., Nickel J., Ploeger F.,
RA   Sebald W., Mueller T., Knaus P.;
RT   "New insights into the molecular mechanism of multiple synostoses
RT   syndrome (SYNS): mutation within the GDF5 knuckle epitope causes
RT   noggin-resistance.";
RL   J. Bone Miner. Res. 27:429-442(2012).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 33-131, AND DISULFIDE BONDS.
RX   PubMed=17094948; DOI=10.1016/j.bbrc.2006.10.109;
RA   Mace P.D., Cutfield J.F., Cutfield S.M.;
RT   "High resolution structures of the bone morphogenetic protein type II
RT   receptor in two crystal forms: implications for ligand binding.";
RL   Biochem. Biophys. Res. Commun. 351:831-838(2006).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 189-517 IN COMPLEX WITH ADP.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the BMPR2 kinase domain.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [14]
RP   VARIANTS PPH1 GLN-491 AND TRP-491.
RX   PubMed=10903931; DOI=10.1086/303059;
RA   Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G.,
RA   Kalachikov S., Cayanis E., Fischer S.G., Barst R.J., Hodge S.E.,
RA   Knowles J.A.;
RT   "Familial primary pulmonary hypertension (gene PPH1) is caused by
RT   mutations in the bone morphogenetic protein receptor-II gene.";
RL   Am. J. Hum. Genet. 67:737-744(2000).
RN   [15]
RP   VARIANTS PPH1 TYR-60; TYR-117 AND ARG-483.
RX   PubMed=11015450; DOI=10.1136/jmg.37.10.741;
RA   Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M.,
RA   Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J.H.,
RA   Wheeler L., Higenbottam T., Gibbs J.S.R., Egan J., Crozier A.,
RA   Peacock A., Allcock R., Corris P., Loyd J.E., Trembath R.C.,
RA   Nichols W.C.;
RT   "Sporadic primary pulmonary hypertension is associated with germline
RT   mutations of the gene encoding BMPR-II, a receptor member of the TGF-
RT   beta family.";
RL   J. Med. Genet. 37:741-745(2000).
RN   [16]
RP   VARIANTS PPH1 TRP-118; TYR-347 AND GLY-485.
RX   PubMed=10973254; DOI=10.1038/79226;
RA   Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R.,
RA   Phillips J.A. III, Loyd J.E., Nichols W.C., Trembath R.C., Aldred M.,
RA   Brannon C.A., Conneally P.M., Foroud T., Fretwell N., Gaddipati R.,
RA   Koller D., Loyd E.J., Morgan N.V., Newman J.H., Prince M.A.,
RA   Vilarino Gueell C., Wheeler L.;
RT   "Heterozygous germline mutations in BMPR2, encoding a TGF-beta
RT   receptor, cause familial primary pulmonary hypertension.";
RL   Nat. Genet. 26:81-84(2000).
RN   [17]
RP   VARIANTS PPH1 ARG-123; SER-123; ARG-420 AND THR-512, VARIANT ASP-224,
RP   AND CHARACTERIZATION OF VARIANT PPH1 GLY-485.
RX   PubMed=11115378; DOI=10.1086/316947;
RA   Machado R.D., Pauciulo M.W., Thomson J.R., Lane K.B., Morgan N.V.,
RA   Wheeler L., Phillips J.A. III, Newman J.H., Williams D., Galie N.,
RA   Manes A., McNeil K., Yacoub M., Mikhail G., Rogers P., Corris P.,
RA   Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E.,
RA   Trembath R.C., Nichols W.C.;
RT   "BMPR2 haploinsufficiency as the inherited molecular mechanism for
RT   primary pulmonary hypertension.";
RL   Am. J. Hum. Genet. 68:92-102(2001).
RN   [18]
RP   VARIANTS PPH1 HIS-82; ASP-182 AND ARG-483.
RX   PubMed=12358323; DOI=10.1183/09031936.02.01762002;
RA   Humbert M., Deng Z., Simonneau G., Barst R.J., Sitbon O., Wolf M.,
RA   Cuervo N., Moore K.J., Hodge S.E., Knowles J.A., Morse J.H.;
RT   "BMPR2 germline mutations in pulmonary hypertension associated with
RT   fenfluramine derivatives.";
RL   Eur. Respir. J. 20:518-523(2002).
RN   [19]
RP   INVOLVEMENT IN PVOD1.
RX   PubMed=12446270; DOI=10.1164/rccm.200208-861OC;
RA   Runo J.R., Vnencak-Jones C.L., Prince M., Loyd J.E., Wheeler L.,
RA   Robbins I.M., Lane K.B., Newman J.H., Johnson J., Nichols W.C.,
RA   Phillips J.A. III;
RT   "Pulmonary veno-occlusive disease caused by an inherited mutation in
RT   bone morphogenetic protein receptor II.";
RL   Am. J. Respir. Crit. Care Med. 167:889-894(2003).
RN   [20]
RP   VARIANT PPH1 PRO-899, AND CHARACTERIZATION OF VARIANT PPH1 PRO-899.
RX   PubMed=15965979; DOI=10.1002/humu.20200;
RA   Sankelo M., Flanagan J.A., Machado R., Harrison R., Rudarakanchana N.,
RA   Morrell N., Dixon M., Halme M., Puolijoki H., Kere J., Elomaa O.,
RA   Kupari M., Raeisaenen-Sokolowski A., Trembath R.C., Laitinen T.;
RT   "BMPR2 mutations have short lifetime expectancy in primary pulmonary
RT   hypertension.";
RL   Hum. Mutat. 26:119-124(2005).
RN   [21]
RP   INVOLVEMENT IN PVOD1.
RX   PubMed=16429395; DOI=10.1002/humu.20285;
RA   Machado R.D., Aldred M.A., James V., Harrison R.E., Patel B.,
RA   Schwalbe E.C., Gruenig E., Janssen B., Koehler R., Seeger W.,
RA   Eickelberg O., Olschewski H., Elliott C.G., Glissmeyer E.,
RA   Carlquist J., Kim M., Torbicki A., Fijalkowska A., Szewczyk G.,
RA   Parma J., Abramowicz M.J., Galie N., Morisaki H., Kyotani S.,
RA   Nakanishi N., Morisaki T., Humbert M., Simonneau G., Sitbon O.,
RA   Soubrier F., Coulet F., Morrell N.W., Trembath R.C.;
RT   "Mutations of the TGF-beta type II receptor BMPR2 in pulmonary
RT   arterial hypertension.";
RL   Hum. Mutat. 27:121-132(2006).
RN   [22]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-775.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [23]
RP   VARIANTS PPH1 CYS-67 AND ASN-863, CHARACTERIZATION OF VARIANTS PPH1
RP   CYS-67 AND ASN-863, AND SUBCELLULAR LOCATION.
RX   PubMed=25187962; DOI=10.1371/journal.pone.0106703;
RA   Wang H., Ji R., Meng J., Cui Q., Zou W., Li L., Wang G., Sun L.,
RA   Li Z., Huo L., Fan Y., Penny D.J.;
RT   "Functional changes in pulmonary arterial endothelial cells associated
RT   with BMPR2 mutations.";
RL   PLoS ONE 9:E106703-E106703(2014).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Binds to BMP7, BMP2 and, less
CC       efficiently, BMP4. Binding is weak but enhanced by the presence of
CC       type I receptors for BMPs. Mediates induction of adipogenesis by
CC       GDF6. {ECO:0000250|UniProtKB:O35607}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with GDF5. {ECO:0000269|PubMed:21976273}.
CC   -!- INTERACTION:
CC       P08607:C4bpa (xeno); NbExp=3; IntAct=EBI-527196, EBI-527325;
CC       P43026:GDF5; NbExp=4; IntAct=EBI-527196, EBI-8571476;
CC       P68404:Prkcb (xeno); NbExp=4; IntAct=EBI-527196, EBI-397048;
CC       Q13976:PRKG1; NbExp=2; IntAct=EBI-527196, EBI-3952014;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25187962};
CC       Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13873-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13873-2; Sequence=VSP_054441, VSP_054442;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart and liver.
CC   -!- DISEASE: Pulmonary hypertension, primary, 1 (PPH1) [MIM:178600]: A
CC       rare disorder characterized by plexiform lesions of proliferating
CC       endothelial cells in pulmonary arterioles. The lesions lead to
CC       elevated pulmonary arterial pression, right ventricular failure,
CC       and death. The disease can occur from infancy throughout life and
CC       it has a mean age at onset of 36 years. Penetrance is reduced.
CC       Although familial pulmonary hypertension is rare, cases secondary
CC       to known etiologies are more common and include those associated
CC       with the appetite-suppressant drugs. {ECO:0000269|PubMed:10903931,
CC       ECO:0000269|PubMed:10973254, ECO:0000269|PubMed:11015450,
CC       ECO:0000269|PubMed:11115378, ECO:0000269|PubMed:12358323,
CC       ECO:0000269|PubMed:15965979, ECO:0000269|PubMed:25187962}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Pulmonary venoocclusive disease 1, autosomal dominant
CC       (PVOD1) [MIM:265450]: A disease characterized by widespread
CC       fibrous obstruction and intimal thickening of septal veins and
CC       preseptal venules, a low diffusing capacity for carbon monoxide,
CC       occult alveolar hemorrhage, and nodular ground-glass opacities,
CC       septal lines and lymph node enlargement showed by high-resolution
CC       computed tomography of the chest. It is frequently associated with
CC       pulmonary capillary dilatation and proliferation, and is a rare
CC       and devastating cause of pulmonary hypertension.
CC       {ECO:0000269|PubMed:12446270, ECO:0000269|PubMed:16429395}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U25110; AAA86519.1; -; mRNA.
DR   EMBL; Z48923; CAA88759.1; -; mRNA.
DR   EMBL; D50516; BAA09094.1; -; mRNA.
DR   EMBL; U20165; AAC50105.1; -; mRNA.
DR   EMBL; AC009960; AAX76517.1; -; Genomic_DNA.
DR   EMBL; AC073410; AAX88941.1; -; Genomic_DNA.
DR   EMBL; AC064836; AAY24146.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70309.1; -; Genomic_DNA.
DR   EMBL; BC052985; AAH52985.1; -; mRNA.
DR   CCDS; CCDS33361.1; -. [Q13873-1]
DR   PIR; I38935; I38935.
DR   RefSeq; NP_001195.2; NM_001204.6. [Q13873-1]
DR   UniGene; Hs.471119; -.
DR   PDB; 2HLQ; X-ray; 1.45 A; A=33-131.
DR   PDB; 3G2F; X-ray; 2.35 A; A/B=189-517.
DR   PDBsum; 2HLQ; -.
DR   PDBsum; 3G2F; -.
DR   ProteinModelPortal; Q13873; -.
DR   SMR; Q13873; -.
DR   BioGrid; 107127; 56.
DR   DIP; DIP-5794N; -.
DR   IntAct; Q13873; 34.
DR   MINT; MINT-124272; -.
DR   STRING; 9606.ENSP00000363708; -.
DR   BindingDB; Q13873; -.
DR   ChEMBL; CHEMBL5467; -.
DR   GuidetoPHARMACOLOGY; 1794; -.
DR   iPTMnet; Q13873; -.
DR   PhosphoSitePlus; Q13873; -.
DR   BioMuta; BMPR2; -.
DR   DMDM; 12643724; -.
DR   EPD; Q13873; -.
DR   MaxQB; Q13873; -.
DR   PaxDb; Q13873; -.
DR   PeptideAtlas; Q13873; -.
DR   PRIDE; Q13873; -.
DR   DNASU; 659; -.
DR   Ensembl; ENST00000374574; ENSP00000363702; ENSG00000204217. [Q13873-2]
DR   Ensembl; ENST00000374580; ENSP00000363708; ENSG00000204217. [Q13873-1]
DR   GeneID; 659; -.
DR   KEGG; hsa:659; -.
DR   UCSC; uc002uzf.5; human. [Q13873-1]
DR   CTD; 659; -.
DR   DisGeNET; 659; -.
DR   GeneCards; BMPR2; -.
DR   GeneReviews; BMPR2; -.
DR   HGNC; HGNC:1078; BMPR2.
DR   HPA; HPA017385; -.
DR   HPA; HPA049014; -.
DR   MalaCards; BMPR2; -.
DR   MIM; 178600; phenotype.
DR   MIM; 265450; phenotype.
DR   MIM; 600799; gene.
DR   neXtProt; NX_Q13873; -.
DR   OpenTargets; ENSG00000204217; -.
DR   Orphanet; 275777; Heritable pulmonary arterial hypertension.
DR   Orphanet; 275766; Idiopathic pulmonary arterial hypertension.
DR   Orphanet; 31837; Pulmonary venoocclusive disease.
DR   PharmGKB; PA25388; -.
DR   eggNOG; KOG3653; Eukaryota.
DR   eggNOG; ENOG410XS2Z; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000043088; -.
DR   HOVERGEN; HBG050705; -.
DR   InParanoid; Q13873; -.
DR   KO; K04671; -.
DR   OMA; HATNVAQ; -.
DR   OrthoDB; EOG091G03YO; -.
DR   PhylomeDB; Q13873; -.
DR   TreeFam; TF314724; -.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; Q13873; -.
DR   SIGNOR; Q13873; -.
DR   ChiTaRS; BMPR2; human.
DR   EvolutionaryTrace; Q13873; -.
DR   GeneWiki; BMPR2; -.
DR   GenomeRNAi; 659; -.
DR   PRO; PR:Q13873; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000204217; -.
DR   CleanEx; HS_BMPR2; -.
DR   Genevisible; Q13873; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0009925; C:basal plasma membrane; IEA:Ensembl.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005913; C:cell-cell adherens junction; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0044214; C:spanning component of plasma membrane; TAS:AgBase.
DR   GO; GO:0016362; F:activin receptor activity, type II; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0036122; F:BMP binding; IPI:UniProtKB.
DR   GO; GO:0098821; F:BMP receptor activity; ISS:UniProtKB.
DR   GO; GO:0019838; F:growth factor binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; ISS:BHF-UCL.
DR   GO; GO:0060840; P:artery development; ISS:BHF-UCL.
DR   GO; GO:0060413; P:atrial septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001974; P:blood vessel remodeling; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0009267; P:cellular response to starvation; IEP:BHF-UCL.
DR   GO; GO:0002063; P:chondrocyte development; IMP:AgBase.
DR   GO; GO:0003197; P:endocardial cushion development; ISS:BHF-UCL.
DR   GO; GO:0060350; P:endochondral bone morphogenesis; ISS:AgBase.
DR   GO; GO:0072577; P:endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0001935; P:endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0060173; P:limb development; IEA:Ensembl.
DR   GO; GO:0048286; P:lung alveolus development; ISS:BHF-UCL.
DR   GO; GO:0001946; P:lymphangiogenesis; ISS:BHF-UCL.
DR   GO; GO:0060836; P:lymphatic endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0001893; P:maternal placenta development; IEA:Ensembl.
DR   GO; GO:0001707; P:mesoderm formation; ISS:BHF-UCL.
DR   GO; GO:0003183; P:mitral valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0003252; P:negative regulation of cell proliferation involved in heart valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1902731; P:negative regulation of chondrocyte proliferation; IMP:AgBase.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0003085; P:negative regulation of systemic arterial blood pressure; IMP:BHF-UCL.
DR   GO; GO:0045906; P:negative regulation of vasoconstriction; ISS:BHF-UCL.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0061626; P:pharyngeal arch artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048842; P:positive regulation of axon extension involved in axon guidance; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0061036; P:positive regulation of cartilage development; ISS:AgBase.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IDA:UniProtKB.
DR   GO; GO:0045778; P:positive regulation of ossification; ISS:BHF-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0030166; P:proteoglycan biosynthetic process; ISS:AgBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:HGNC.
DR   GO; GO:0014916; P:regulation of lung blood pressure; IMP:BHF-UCL.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:BHF-UCL.
DR   GO; GO:1905314; P:semi-lunar valve development; ISS:BHF-UCL.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0007178; P:transmembrane receptor protein serine/threonine kinase signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0060841; P:venous blood vessel development; ISS:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR015770; BMPR2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   PANTHER; PTHR23255:SF82; PTHR23255:SF82; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27   1038       Bone morphogenetic protein receptor type-
FT                                2.
FT                                /FTId=PRO_0000024415.
FT   TOPO_DOM     27    150       Extracellular. {ECO:0000255}.
FT   TRANSMEM    151    171       Helical. {ECO:0000255}.
FT   TOPO_DOM    172   1038       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      203    504       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     209    217       ATP. {ECO:0000305|Ref.13}.
FT   NP_BIND     280    282       ATP. {ECO:0000305|Ref.13}.
FT   NP_BIND     337    338       ATP. {ECO:0000305|Ref.13}.
FT   COMPBIAS    547    550       Poly-Ser.
FT   COMPBIAS    610    618       Poly-Thr.
FT   COMPBIAS    901    908       Poly-Asn.
FT   ACT_SITE    333    333       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     230    230       ATP. {ECO:0000305|Ref.13}.
FT   BINDING     351    351       ATP. {ECO:0000305|Ref.13}.
FT   MOD_RES     379    379       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     586    586       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     680    680       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O35607}.
FT   MOD_RES     681    681       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O35607}.
FT   CARBOHYD     55     55       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    110    110       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    126    126       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     34     66       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   DISULFID     60     84       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   DISULFID     94    117       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   DISULFID     99    116       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   DISULFID    118    123       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   VAR_SEQ     530    530       N -> R (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7791754}.
FT                                /FTId=VSP_054441.
FT   VAR_SEQ     531   1038       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7791754}.
FT                                /FTId=VSP_054442.
FT   VARIANT      60     60       C -> Y (in PPH1).
FT                                {ECO:0000269|PubMed:11015450}.
FT                                /FTId=VAR_013670.
FT   VARIANT      67     67       Y -> C (in PPH1; significant decrease in
FT                                nitric oxide synthesis by endothelial
FT                                cells). {ECO:0000269|PubMed:25187962}.
FT                                /FTId=VAR_073041.
FT   VARIANT      82     82       Q -> H (in PPH1).
FT                                {ECO:0000269|PubMed:12358323}.
FT                                /FTId=VAR_033109.
FT   VARIANT     117    117       C -> Y (in PPH1).
FT                                {ECO:0000269|PubMed:11015450}.
FT                                /FTId=VAR_013671.
FT   VARIANT     118    118       C -> W (in PPH1; dbSNP:rs137852743).
FT                                {ECO:0000269|PubMed:10973254}.
FT                                /FTId=VAR_013672.
FT   VARIANT     123    123       C -> R (in PPH1; dbSNP:rs137852750).
FT                                {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013673.
FT   VARIANT     123    123       C -> S (in PPH1; dbSNP:rs137852750).
FT                                {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013674.
FT   VARIANT     182    182       G -> D (in PPH1; dbSNP:rs137852754).
FT                                {ECO:0000269|PubMed:12358323}.
FT                                /FTId=VAR_033110.
FT   VARIANT     224    224       E -> D (in dbSNP:rs754343081).
FT                                {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013675.
FT   VARIANT     347    347       C -> Y (in PPH1; dbSNP:rs137852744).
FT                                {ECO:0000269|PubMed:10973254}.
FT                                /FTId=VAR_013676.
FT   VARIANT     420    420       C -> R (in PPH1).
FT                                {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013677.
FT   VARIANT     483    483       C -> R (in PPH1; sporadic).
FT                                {ECO:0000269|PubMed:11015450,
FT                                ECO:0000269|PubMed:12358323}.
FT                                /FTId=VAR_013678.
FT   VARIANT     485    485       D -> G (in PPH1; complete loss of
FT                                function; dbSNP:rs137852745).
FT                                {ECO:0000269|PubMed:10973254,
FT                                ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013679.
FT   VARIANT     491    491       R -> Q (in PPH1; sporadic;
FT                                dbSNP:rs137852749).
FT                                {ECO:0000269|PubMed:10903931}.
FT                                /FTId=VAR_013680.
FT   VARIANT     491    491       R -> W (in PPH1; dbSNP:rs137852746).
FT                                {ECO:0000269|PubMed:10903931}.
FT                                /FTId=VAR_013681.
FT   VARIANT     512    512       K -> T (in PPH1).
FT                                {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013682.
FT   VARIANT     519    519       N -> K (in PPH1).
FT                                /FTId=VAR_013683.
FT   VARIANT     775    775       S -> N (in dbSNP:rs2228545).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_019996.
FT   VARIANT     863    863       S -> N (in PPH1; abnormal subcellular
FT                                localization; significant increase in
FT                                apoptosis of endothelial cells;
FT                                significant decrease in proliferation of
FT                                endothelial cells; significant decrease
FT                                in nitric oxide synthesis by endothelial
FT                                cells; significant increase in endothelin
FT                                1 synthesis by endothelial cells).
FT                                {ECO:0000269|PubMed:25187962}.
FT                                /FTId=VAR_073042.
FT   VARIANT     899    899       R -> P (in PPH1; leads to constitutive
FT                                activation of the MAPK14 pathway;
FT                                dbSNP:rs137852752).
FT                                {ECO:0000269|PubMed:15965979}.
FT                                /FTId=VAR_033111.
FT   CONFLICT    828    828       G -> R (in Ref. 2; CAA88759).
FT                                {ECO:0000305}.
FT   STRAND       33     35       {ECO:0000244|PDB:2HLQ}.
FT   TURN         42     47       {ECO:0000244|PDB:2HLQ}.
FT   HELIX        48     50       {ECO:0000244|PDB:2HLQ}.
FT   TURN         53     56       {ECO:0000244|PDB:2HLQ}.
FT   STRAND       57     59       {ECO:0000244|PDB:2HLQ}.
FT   STRAND       66     73       {ECO:0000244|PDB:2HLQ}.
FT   STRAND       76     84       {ECO:0000244|PDB:2HLQ}.
FT   STRAND       90     92       {ECO:0000244|PDB:2HLQ}.
FT   TURN        105    109       {ECO:0000244|PDB:2HLQ}.
FT   STRAND      113    118       {ECO:0000244|PDB:2HLQ}.
FT   HELIX       123    125       {ECO:0000244|PDB:2HLQ}.
FT   STRAND      202    211       {ECO:0000244|PDB:3G2F}.
FT   STRAND      213    222       {ECO:0000244|PDB:3G2F}.
FT   STRAND      225    233       {ECO:0000244|PDB:3G2F}.
FT   HELIX       234    236       {ECO:0000244|PDB:3G2F}.
FT   HELIX       237    247       {ECO:0000244|PDB:3G2F}.
FT   STRAND      260    267       {ECO:0000244|PDB:3G2F}.
FT   STRAND      273    279       {ECO:0000244|PDB:3G2F}.
FT   HELIX       287    293       {ECO:0000244|PDB:3G2F}.
FT   HELIX       298    316       {ECO:0000244|PDB:3G2F}.
FT   HELIX       322    324       {ECO:0000244|PDB:3G2F}.
FT   STRAND      338    341       {ECO:0000244|PDB:3G2F}.
FT   STRAND      347    349       {ECO:0000244|PDB:3G2F}.
FT   STRAND      359    362       {ECO:0000244|PDB:3G2F}.
FT   HELIX       380    382       {ECO:0000244|PDB:3G2F}.
FT   HELIX       385    388       {ECO:0000244|PDB:3G2F}.
FT   HELIX       394    396       {ECO:0000244|PDB:3G2F}.
FT   HELIX       397    417       {ECO:0000244|PDB:3G2F}.
FT   HELIX       421    423       {ECO:0000244|PDB:3G2F}.
FT   HELIX       437    440       {ECO:0000244|PDB:3G2F}.
FT   HELIX       446    453       {ECO:0000244|PDB:3G2F}.
FT   HELIX       471    483       {ECO:0000244|PDB:3G2F}.
FT   HELIX       488    490       {ECO:0000244|PDB:3G2F}.
FT   HELIX       494    506       {ECO:0000244|PDB:3G2F}.
SQ   SEQUENCE   1038 AA;  115201 MW;  1389923CE574B913 CRC64;
     MTSSLQRPWR VPWLPWTILL VSTAAASQNQ ERLCAFKDPY QQDLGIGESR ISHENGTILC
     SKGSTCYGLW EKSKGDINLV KQGCWSHIGD PQECHYEECV VTTTPPSIQN GTYRFCCCST
     DLCNVNFTEN FPPPDTTPLS PPHSFNRDET IIIALASVSV LAVLIVALCF GYRMLTGDRK
     QGLHSMNMME AAASEPSLDL DNLKLLELIG RGRYGAVYKG SLDERPVAVK VFSFANRQNF
     INEKNIYRVP LMEHDNIARF IVGDERVTAD GRMEYLLVME YYPNGSLCKY LSLHTSDWVS
     SCRLAHSVTR GLAYLHTELP RGDHYKPAIS HRDLNSRNVL VKNDGTCVIS DFGLSMRLTG
     NRLVRPGEED NAAISEVGTI RYMAPEVLEG AVNLRDCESA LKQVDMYALG LIYWEIFMRC
     TDLFPGESVP EYQMAFQTEV GNHPTFEDMQ VLVSREKQRP KFPEAWKENS LAVRSLKETI
     EDCWDQDAEA RLTAQCAEER MAELMMIWER NKSVSPTVNP MSTAMQNERN LSHNRRVPKI
     GPYPDYSSSS YIEDSIHHTD SIVKNISSEH SMSSTPLTIG EKNRNSINYE RQQAQARIPS
     PETSVTSLST NTTTTNTTGL TPSTGMTTIS EMPYPDETNL HTTNVAQSIG PTPVCLQLTE
     EDLETNKLDP KEVDKNLKES SDENLMEHSL KQFSGPDPLS STSSSLLYPL IKLAVEATGQ
     QDFTQTANGQ ACLIPDVLPT QIYPLPKQQN LPKRPTSLPL NTKNSTKEPR LKFGSKHKSN
     LKQVETGVAK MNTINAAEPH VVTVTMNGVA GRNHSVNSHA ATTQYANGTV LSGQTTNIVT
     HRAQEMLQNQ FIGEDTRLNI NSSPDEHEPL LRREQQAGHD EGVLDRLVDR RERPLEGGRT
     NSNNNNSNPC SEQDVLAQGV PSTAADPGPS KPRRAQRPNS LDLSATNVLD GSSIQIGEST
     QDGKSGSGEK IKKRVKTPYS LKRWRPSTWV ISTESLDCEV NNNGSNRAVH SKSSTAVYLA
     EGGTATTMVS KDIGMNCL
//
